The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study

Journal of Urology

Volumn 185, Issue 1, 2011, Pages 126-131

  Andriole, Gerald L ^a   Bostwick, David ^b   Brawley, Otis W ^c   Gomella, Leonard ^d   Marberger, Michael ^e   Montorsi, Francesco ^f   Pettaway, Curtis ^g   Tammela, Teuvo L J ^h   Teloken, Claudio ⁱ   Tindall, Donald ^j   Freedland, Stephen J ^k   Somerville, Matthew C ^l   Wilson, Timothy H ^l   Fowler, Ivy ^l   Castro, Ramiro ^l   Rittmaster, Roger S ^l  

^a WASHINGTON UNIVERSITY   (United States)

^b BOSTWICK LABORATORIES   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF TEXAS   (United States)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^j MAYO CLINIC   (United States)

^k DUKE UNIVERSITY   (United States)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

Dutasteride; Prostate specific antigen; Prostatic neoplasms; Sensitivity and specificity

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK REDUCTION; SENSITIVITY AND SPECIFICITY;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; BIOPSY; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78649997059     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.09.011     Document Type: Article

References (13)

1. E.D. Crawford, and P.A. Abrahamsson PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 54 2008 262
2. C.H. Bangma, S. Roemeling, and F.H. Schroder Overdiagnosis and overtreatment of early detected prostate cancer World J Urol 25 2007 3
3. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192.
4. P.C. Walsh Three considerations before advising 5-alpha-reductase inhibitors for chemoprevention J Clin Oncol 27 2009 e22
5. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial J Urol 172 2004 1314
6. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
7. G.L. Andriole, M. Marberger, and C.G. Roehrborn Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride J Urol 175 2006 1657
8. G.L. Andriole, H.A. Guess, J.I. Epstein PLESS Study Group Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial Proscar Long-term Efficacy and Safety Study Urology 52 1998 195
9. B. Djavan, V. Ravery, and A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679
10. K.A. Roehl, J.A. Antenor, and W.J. Catalona Serial biopsy results in prostate cancer screening study J Urol 167 2002 2435
11. I.M. Thompson, D.P. Ankerst, and C. Chi Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial J Clin Oncol 25 2007 3076
12. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128
13. M.S. Lucia, J.I. Epstein, and P.J. Goodman Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1375